Smith and Nephew plc (SNN) |
| 30.57 0.8 (2.69%) 07-24 16:00 |
| Open: | 30.09 |
| High: | 30.6177 |
| Low: | 30.02 |
| Volume: | 1,173,540 |
| Market Cap: | 12,870(M) |
| PE Ratio: | 16.51 |
| Exchange: | New York Stock Exchange |
| Industry: | Medical - Devices |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 36.83 |
| Resistance 1: | 31.53 |
| Pivot price: | 30.45 |
| Support 1: | 29.69 |
| Support 2: | 28.56 |
| 52w High: | 38.79 |
| 52w Low: | 28.56 |
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
| EPS | 1.450 |
| Book Value | 2.490 |
| PEG Ratio | 1.18 |
| Gross Profit | 9.988 |
| Profit Margin (%) | 10.14 |
| Operating Margin (%) | 13.99 |
| Return on Assets (ttm) | 5.3 |
| Return on Equity (ttm) | 11.8 |
Sat, 25 Jul 2026
Smith & Nephew PLC (SNN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Fri, 24 Jul 2026
TradingKey - TradingKey
Thu, 23 Jul 2026
Smith+Nephew Expands ASC Platform to Support Value-Based Care - Yahoo Finance
Thu, 23 Jul 2026
Smith+Nephew (NYSE: SNN) schedules Q2 and H1 2026 results call - Stock Titan
Wed, 22 Jul 2026
Smith+Nephew introduces expanded enterprise ASC Solutions Strategy to support growth, performance and value-based care - Sahm
Wed, 22 Jul 2026
Bank of America reports 3.172736% voting stake in Smith & Nephew (NYSE: SNN) - Stock Titan
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |